 BOSTON, Aug. 31, 2022 GLOBE NEWSWIRE -- AVEO Oncology Nasdaq: AVEO, a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, today announced that members of its senior management team are scheduled to participate in three investor conferences in September, including: 